Join our community of smart investors

Clinigen moves into consolidation phase

The specialist drug company pre-flagged most of these numbers, and is looking to bed in its recent slew of acquisitions
Clinigen moves into consolidation phase

Clinigen (CLIN) shares hardly budged on the release of these half-year numbers, but that should come as little surprise. Key figures – including gross and cash profit – had been pre-announced, while the stock was marked-up following the recent $210m (£163m) acquisition of US rights to cancer drug Proleukin from Swiss pharma giant Novartis (NOVN). So there's plenty of positive sentiment bound up with the share price.

IC TIP: Buy at 926p

To continue reading...
Join our Community of Smart Investors
  • Independent full-length company analysis
  • Actionable investment ideas and recommendations
  • Expert investment tools and data
  • Stock screens from Algy Hall
Have an account? Sign in